This article is brought to you in association with the European Commission.
Today, the Commission’s Health Preparedness and Response Authority (HERA) signed a Joint Procurement Framework Agreement for the supply of Paxlovid, an oral protease inhibitor treatment for SARS-CoV- 2 for patients with COVID-19 at risk of developing severe disease. The contract is signed with the pharmaceutical company Pfizer and will run for an initial period of 12 months.
Thirteen EU and EEA member states and EU candidate countries participate in the market. They will be able to purchase up to 3,427,517 five-day courses of orally administered Paxlovid.
Paxlovid can be used for the treatment of COVID-19 in adults who do not need supplemental oxygen and who are at increased risk of the disease becoming serious. Paxlovid is expected to be effective against current dominant and circulating strains of the virus.
The Commission is committed to building a stronger and more active European Health Union, which is prepared and able to respond to emerging health threats. The COVID-19 pandemic has shown the importance of coordination between European countries and the added value of a common response to cross-border health threats.
The EU Joint Purchasing Agreement offers 36 participating countries the opportunity to jointly procure medical countermeasures as an alternative or complement to national procurement.
HERA continues to work closely with participating countries to identify and implement joint procurement priorities.
The aim of the joint purchasing mechanism is to ensure fairer access to specific medical countermeasures and to improve security of supply, as well as more balanced prices for participating EU countries.